Continuing chemotherapy or not after the induction treatment in advanced breast cancer patients: Clinical outcomes and oncologists' preferences

European Journal of Cancer

Volumn 39, Issue 5, 2003, Pages 614-621

  Nooij, M A ^a   De Haes, J C J M ^b   Beex, L V A M ^c   Wildiers, J ^d   Klijn, J ^e   Becquart, D ^f   Jassem, J ^g   Engelsman, E ^h   Duchateau, L ⁱ  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f MIDDELHEIM HOSPITAL   (Belgium)

^g MEDICAL UNIVERSITY OF GDANSK   (Poland)

^h NETHERLANDS CANCER INSTITUTE   (Netherlands)

ⁱ EORTC DATA CENTER   (Belgium)

Author keywords

Duration of chemotherapy; Metastatic breast cancer; Physicians' preferences; Q TwiST

Indexed keywords

CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE; ANTINEOPLASTIC AGENT; CMF REGIMEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; ONCOLOGY; PHYSICIAN ATTITUDE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME; TREATMENT FAILURE; TREATMENT OUTCOME; BREAST TUMOR; CLINICAL PRACTICE; DECISION MAKING; DISEASE FREE SURVIVAL; MIDDLE AGED; MULTICENTER STUDY; RISK FACTOR; SURVIVAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DECISION MAKING; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; METHOTREXATE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 0037333624     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(02)00869-9     Document Type: Article

References (19)

1. Coates A., Gebski V., Bishop J.F.et al. Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. N. Engl. J. Med. 317:1987;1490-1495.
2. Harris A.L., Cantwell B.M., Carmichael J.et al. Comparison of short-term and continuous chemotherapy (mitozantrone) for advanced breast cancer. Lancet. 335:1990;186-190.
3. Muss H.B., Case L.D., Richards F.et al. Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Piedmont Oncology Association. N. Engl. J. Med. 325:1991;1342-1348.
4. Ejlertsen B., Pfeiffer P., Pedersen D.et al. Decreased efficacy of cyclophosphamide, epirubicin and 5-fluorouracil in metastatic breast cancer when reducing treatment duration from 18 to 6 months. Eur. J. Cancer. 29A:1993;527-531.
5. Gregory R.K., Powles T.J., Chang J.C.et al. A randomised trial of six versus twelve courses of chemotherapy in metastatic carcinoma of the breast. Eur. J. Cancer. 33:1997;2194-2197.
6. Falkson G., Gelman R.S., Pandya K.J.et al. Eastern cooperative oncology group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment. J. Clin. Oncol. 16:1998;1669-1676.
7. Miller K.D., Sledge G.W. Jr. The role of chemotherapy for metastatic breast cancer. Hematol. Oncol. Clin. North Am. 13:1999;415-434.
8. Epirubicin-based chemotherapy in metastatic breast cancer patients. role of dose-indensity and duration of treatment J. Clin. Oncol. 18:2000;3115-3124.
9. Engelsman E., Klijn J.C., Rubens R.D.et al. "Classical" CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. An EORTC Breast Cancer Co-operative Group Phase III Trial (10808). Eur. J. Cancer. 27:1991;966-970.
10. Hayward J.L., Rubens R.D., Carbone P.P.et al. Assessment of response to therapy in advanced breast cancer. A project of the programme on clinical oncology of the International Union against Cancer, Geneva, Switzerland. Eur. J. Cancer. 41:1978;1291-1292.
11. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J. Am. Statist. Ass. 53:1958;457-481.
12. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother. Rep. 50:1966;163-170.
13. Goldhirsch A., Gelber R.D., Simes R.J.et al. Costs and benefits of adjuvant therapy in breast cancer. a quality-adjusted survival analysis J. Clin. Oncol. 7:1989;36-44.
14. Gelber R.D., Cole B.F., Goldhirsch A.et al. Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer. meta-analysis of quality-adjusted survival Lancet. 347:1996;1066-1071.
15. Glasziou P.P., Simes R.J., Gelber R.D. Quality adjusted survival analysis. Stat. Med. 9:1990;1259-1276.
16. Cole B.F., Gelber R.D., Goldhirsch A. Cox regression models for quality adjusted survival analysis. Stat. Med. 12:1993;975-987.
17. Ellis M.J., Hayes D.F., Lippman M.E. Treatment of metastatic breast cancer. Harris J.R., Lippman M.E., Morrow M., Osborne C.K. Diseases of the Breast. 2nd edn. 2000;775-783 Lippincott Williams & Wilkins, Philadelphia.
18. Stiggelbout A.M., Eijkemans M.J., Kiebert G.M., Kievit J., Leer J.W., De Haes H.J. The 'utility' of the visual analog scale in medical decision making and technology assessment. Is it an alternative to the time trade-off? Int. J. Technol. Assess. Health Care. 12:1996;291-298.
19. Porzsolt F., Tannock I. Goals of palliative cancer therapy. J. Clin. Oncol. 11:1993;378-381.